[Form 4] agilon health, inc. Insider Trading Activity

Rhea-AI Filing Summary

agilon health, inc. (AGL) – Form 4, filed 08/05/2025

Chief Legal Officer Denise Zamore reported a Rule 16b-3 “F” transaction dated 08/01/2025. The issuer withheld 915 common shares at an indicated $1.70 per share to cover income-tax obligations arising from the net settlement of previously granted restricted stock units. Because the shares were withheld by the company rather than sold in the open market, Zamore’s underlying economic exposure to AGL stock is largely unchanged. Following the withholding, she directly owns 443,125 shares (including unvested RSUs); no derivative securities were acquired or disposed of. No other officers or directors were involved, and no additional transactions were disclosed.

The filing is routine and does not signal an intentional sale or purchase. Investors may view the update as neutral but can use it to monitor insider ownership trends and share-based compensation practices.

Insights

Financial Analyst

TL;DR: Routine tax-withholding transaction; negligible impact on ownership or valuation.

The "F" code indicates shares withheld by the company to satisfy taxes on vested RSUs. Only 915 shares (<1% of Zamore’s 443k position) were involved, so the move does not meaningfully alter insider alignment or market float. No price discovery or sentiment signal accompanies the action. I consider the disclosure immaterial for valuation or trading decisions.

Corporate Governance Expert

TL;DR: Standard compliance filing; governance posture unchanged.

The filing demonstrates timely Section 16 compliance and transparent reporting of equity-based compensation settlements. Because it involves mandatory tax withholding rather than elective selling, it poses no governance red flag. Insider ownership remains substantial, supporting ongoing alignment with shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zamore Denise

(Last) (First) (Middle)

C/O AGILON HEALTH, INC.

440 POLARIS PARKWAY, SUITE 550

(Street)

WESTERVILLE OH 43082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
agilon health, inc. [ AGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		F		915(1)	D	$1.7	443,125(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale.

2. Includes restricted stock units.

Remarks:

	/s/ Mimi Yang, as Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many agilon health (AGL) shares did Denise Zamore dispose of?

The filing shows 915 common shares were withheld by the issuer to cover taxes.

Was the transaction an open-market sale of AGL stock?

No. Code "F" denotes share withholding for tax purposes, not an open-market sale.

What is Zamore's total direct ownership after the transaction?

After the withholding, Zamore directly owns 443,125 AGL shares, including RSUs.

Were any derivative securities (options, warrants) involved?

No derivative securities were acquired or disposed of in this Form 4.

Does this Form 4 indicate a change in insider sentiment toward AGL?

The transaction is routine and tax-driven, so it does not provide a meaningful sentiment signal.